BofA Securities Initiates Viridian Therapeutics Coverage With Buy Rating
BofA Securities initiated coverage of Viridian Therapeutics with a Buy rating and a $47 price target.
BofA Securities initiated coverage of Viridian Therapeutics with a Buy rating and a $47 price target.